Evaluation of XXXX _ @entity16332 in chronic @entity1956 : correlation with @entity97 viral kinetic, hepatic-necro inflammation _ @entity82 .

@entity1 @entity97 @entity32 @entity82 @entity16332 @entity24488 @entity1956
BACKGROUND _ OBJECTIVES: Chronic @entity1956 is an important cause of morbidity and mortality. We conducted a study comparing the efficacy of @entity24488 and @entity16332 with respect to their impact on serum and hepatic viral DNA clearance, and improvement in hepatic necro-inflammatory score, in naive @entity1 of chronic @entity1956 . METHODS: This prospective randomized pilot study was conducted in Lok Nayak Hospital, New Delhi, involving 30 @entity1 of chronic @entity1956 (both e antigen positive and negative); 15 were randomly selected to receive either @entity24488 or @entity16332 for a period of 6 months. Quantification of serum and hepatic @entity97 DNA levels was done by real time PCR and liver biopsy was done at the beginning and end of 6 months. RESULTS: Serum ALT was elevated to 2 or more times normalized in both the groups. In the @entity24488 group, two @entity1 became HBeAg negative. In the @entity16332 group, one @entity1 became HBeAg negative. After therapy @entity97 DNA was negative in 26.7 per cent @entity1 from @entity24488 group and 13.3 per cent @entity1 from @entity16332 group. Serum HBV DNA levels were correlated with the hepatic levels before therapy (r=0.843; P<0.001) and after therapy (r=0.713, P<0.001) showing strong correlation. There was a median reduction of 1.92 and 2.06 log copies per ml in serum HBV DNA load after @entity24488 and @entity16332 therapy, respectively. The mean reduction in the histology activity index (HAI) score was 2 and 1.53, @entity82 score was 2.33 and 3.06 after @entity24488 and @entity16332 therapy respectively. INTERPRETATION _ CONCLUSIONS: @entity24488 and @entity16332 treatment caused biochemical and serological improvement when administered for about 6 months with significant reduction in HBV DNA, serum and hepatic viral load without completely clearing the virus from either serum or liver. It also helped in @entity32 and @entity82 score of @entity1 with chronic @entity1956 . Our study also showed significant correlation between serum and hepatic @entity97 DNA levels both before and after therapy. There was not enough evidence to show therapeutic advantage of one drug over the other in any of the parameters measured.
